1. www.eshg.org/111.0.html
, accessed September 2017
2. Genetic Services for Neurological Disorders, ABN and Clinical Genetics Society Report, 2003,
www.clingensoc.org/media/43590/genet_services_neuro.pdf
3. McCarthy A, Lonergan R, Olszewska DA, O’Dowd S, Cummins G, Magennis B, Fallon EM, Pender N, Huey ED, Cosentino S, O’Rourke K, Kelly BD, O’Connell M, Delon I, Farrell M, Spillantini MG, Rowland LP, Fahn S, Craig P, Hutton M, Lynch T (2015) Closing the tau loop: the missing tau mutation. Brain 138(Pt 10):3100–3109
4. Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS),
https://clinicaltrials.gov/ct2/show/NCT01993186
5. Wood NH, Hanna MG (2002) Running a Neurogenetic clinic. JNNP 73(suplI):2–4